Article
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2004
Learn Chris A, Hartzell Tristan L, Wikstrand Carol J, Archer Gary E, Rich Jeremy N, Friedman Allan H, Friedman Henry S, Bigner Darell D, Sampson John H
Abstract excerpt
PURPOSE: We have reported previously that tumors expressing wild-type epidermal growth factor receptor (EGFR) in a murine model are sensitive to the EGFR tyrosine kinase inhibitor gefitinib, whereas tumors expressing mutant EGFR variant III (EGFRvIII) are resistant. Determination of how this diff...
Topics
- Animals
- Cell Division
- Cell Line, Tumor
- Cell Movement
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Enzyme Inhibitors
- ErbB Receptors
- Gefitinib
- Glioblastoma
- Humans
- Mice
- Mutation